Tuncer A M, Hiçsönmez G, Gümrük F, Albayrak D, Duru F, Güzel E, Sayli T
Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey.
Turk J Pediatr. 1995 Oct-Dec;37(4):345-9.
The expression of CD34 antigen on the surface of bone marrow (BM) cells during remission induction was studied in 20 patients with CD34-negative acute myeloblastic leukemia (AML). The patients were given high-dose methylprednisolone (HDMP) alone for one week, after which time mitoxantrone and low-dose Ara-C were added. BM cells from all patients were studied one, two and four weeks after initiation of treatment to evaluate CD34 antigen expression using a three-step peroxidase antiperoxidase staining technique. The mean percentage of CD34-positive BM cells was 5.3% at presentation, increasing to 15.6% in the first week, 12.9% in the second week and 21.7% in the fourth week of therapy. During the same period the mean percentages of the initial BM blasts decreased from 64% to 22%, 7% and 2% in the first, second and fourth weeks of therapy, respectively. The increase in the CD34-positive BM cells one week after HDMP treatment alone suggests that HDMP directly or indirectly stimulates CD34-positive hematopoietic progenitor cells while decreasing BM blasts in patients with AML.
对20例CD34阴性急性髓细胞白血病（AML）患者在缓解诱导期骨髓（BM）细胞表面CD34抗原的表达情况进行了研究。患者单独接受高剂量甲基泼尼松龙（HDMP）治疗一周，之后加入米托蒽醌和小剂量阿糖胞苷。在治疗开始后的1周、2周和4周对所有患者的骨髓细胞进行研究，采用三步过氧化物酶抗过氧化物酶染色技术评估CD34抗原表达。治疗开始时CD34阳性骨髓细胞的平均百分比为5.3%，在治疗的第1周增至15.6%，第2周为12.9%，第4周为21.7%。在同一时期，初始骨髓原始细胞的平均百分比在治疗的第1周、第2周和第4周分别从64%降至22%、7%和2%。单独使用HDMP治疗1周后CD34阳性骨髓细胞增加，这表明HDMP直接或间接刺激CD34阳性造血祖细胞，同时减少AML患者的骨髓原始细胞。
